Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107120 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 312
- Enrollment target
NCT00107120 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 312 participants.
The verdict
NCT00107120, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 312 participants
- Enrollment target
Study Summary
Depression affects approximately 2.5% of children and 8% of adolescents. Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to provide a systematic evaluation of the safety and efficacy of escitalopram in the treatment of depressed pediatric patients, 12 to 17 years of age. Patients completing the study will be eligible to enter an open-label extension study.
Interventions
- DRUG Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107120
The ClinicalTrials.gov registry entry for NCT00107120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00107120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107120 about?
NCT00107120 is a clinical study titled "The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder". Depression affects approximately 2.5% of children and 8% of adolescents. Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to provide a systematic eva...
What is the current status of trial NCT00107120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 312 participants. The study started on 2005-03.
What interventions are being tested in trial NCT00107120?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00107120?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.